Navigation Links
Ontario Cancer Institute, US scientists discover compound that kills lymphoma cells
Date:4/12/2010

An international research team co-led by the Ontario Cancer Institute (OCI) has discovered a compound that kills specific lymphoma cells a discovery that will accelerate developing targeted drugs to fight the most common form of non-Hodgkins lymphoma.

The research findings, published online today in Cancer Cell (DOI 0.1016/j.ccr.2009.12.050), show how the scientists used a chemical compound to block protein BCL6, the cancer-causing culprit in about half of all non-Hodgkins lymphoma cases, the fifth most common type of cancer in Canadians.

Co-principal investigator Dr. Gilbert Priv, an OCI senior scientist who specializes in analyzing the structure and function of cancer-related proteins, says: "We have identified a new avenue for drug development. It is exciting because until now, the prevailing wisdom has been that cancer proteins such as BCL6 would not respond in this way to chemical manipulation. We have proven otherwise."

The scientists began their quest using three-dimensional crystallography and computer-aided drug design to filter over one million potential compounds to about 100 that merited further research. They continued narrowing the field, down to 10 and, eventually, to the one compound that proved successful. In lab experiments, there was even better news not only did the compound kill lymphoma cells, it was also non-toxic.

Dr. Priv explains further: "If you picture cell proteins as a circuit board, we have found a way to short-circuit a defective connection without destroying the entire board. This is the potential of targeted therapy to kill specific cancer cells and leave healthy cells untouched."


'/>"/>

Contact: Jane Finlayson
jane.finlayson@uhn.on.ca
416-946-2846
University Health Network
Source:Eurekalert

Page: 1

Related biology news :

1. Cancer drug effectiveness substantially advanced
2. Disparities persist in outcomes for African-American women with advanced breast cancer
3. The immune systems guard against cancer
4. Chip checks for oral cancer
5. New discovery is a significant boost to cancer research
6. VARI study could improve treatments for prostate cancer
7. New cancer therapy may fight cardiovascular disease
8. Cancer therapy using unique imaging, delivery system focus of NSF CAREER Award
9. Advances reported in quest for drugs targeting childhood cancer
10. Development of new anti-cancer gene therapy approach using lentiviral vectors
11. Specific lymph node radiotherapy is well-tolerated after surgery in early breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2017)... Feb. 2, 2017  EyeLock LLC, a market leader ... white paper " What You Should Know About Biometrics ... ensuring user authenticity is a growing concern. In traditional ... users. However, traditional authentication schemes such as username/password suffer ... Biometric authentication offers an elegant solution to the problem ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
(Date:1/26/2017)... , Jan. 26, 2017  Acuity Market ... for Biometrics and Digital Identity".  Acuity characterizes 2017 ... identity when increased adoption reflects a new understanding ... "Biometrics and digital identity are often ... Maxine Most , Principal of Acuity Market ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ("China ... company in China, today announced its financial results for the ... Fourth Quarter 2016 Financial Highlights Total ... in RMB terms, or increased by 13.6% in USD terms ... of 2015. Gross profit increased by 13.3% ...
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook ... portfolio to include an array of biochemical analyses critical for Lead Discovery. ... their hit-to-lead and SAR programs, including inhibitor potency and selectivity, mechanism of action, ...
(Date:2/23/2017)... ROCHESTER, Minn. , Feb. 23, 2017 /PRNewswire/ ... a new product line of oncolytic vaccinia viruses ... Genelux Corporation as part of Genelux,s proprietary, vaccinia ... "We are excited to enter into a partnership ... time, selected oncolytic vaccinia viruses for use in ...
(Date:2/23/2017)... ... 23, 2017 , ... The Greater Gift Initiative, Inc , (GGI) a ... Research . GGI's mission is to advance global health and highlight the greater good ... honor of each clinical trial volunteer. The vision of GGI is to serve as ...
Breaking Biology Technology: